| Trial | control | p<0.05 | harm | NS |
|---|
| Abraham, 1987 | vs placebo | | | Ventricular tachycardia 0.41 [0.11; 1.49] All cause death 0.96 [0.06; 14.87] Profound hypotension 0.48 [0.04; 5.11] Ventricular fibrillation 0.00 [0.00; NaN] Cardiogenic shock 0.96 [0.06; 14.87] Bradycardia ∞ [NaN; ∞] |
| ISIS-4, 1995 | vs placebo | Ventricular fibrillation 0.91 [0.84; 0.99] | Heart failure 1.07 [1.03; 1.11] Profound hypotension 1.11 [1.07; 1.16] II-III heart block 1.07 [1.03; 1.11] Cardiogenic shock 1.11 [1.03; 1.20] Bradycardia 7.42 [4.06; 13.56] | All cause death 1.06 [0.98; 1.14] |
| MAGIC, 2000 | vs placebo | | | All cause death 1.00 [0.89; 1.13] Heart failure 1.06 [0.95; 1.17] II-III heart block 1.06 [0.95; 1.17] severe arrhythmia 1.01 [0.81; 1.26] |
| Bhargava, 1995 | vs placebo | Ventricular tachycardia 0.48 [0.29; 0.78] | | All cause death 0.95 [0.20; 4.42] Ventricular fibrillation 0.63 [0.11; 3.58] Cardiogenic shock 0.00 [0.00; NaN] Bradycardia 1.90 [0.18; 20.10] |
| Ceremuzynski, 1989 | vs placebo | Ventricular tachycardia 0.36 [0.18; 0.70] | | All cause death 0.31 [0.03; 2.74] Ventricular fibrillation 0.00 [0.00; NaN] Cardiogenic shock ∞ [NaN; ∞] |
| Chen, 1991 | vs placebo | severe arrhythmia 0.35 [0.17; 0.70] | | Ventricular tachycardia 0.00 [0.00; NaN] Ventricular fibrillation 0.00 [0.00; NaN] |
| Feldstedt, 1991 | vs placebo | | | Ventricular tachycardia ∞ [NaN; ∞] All cause death 1.23 [0.50; 3.04] Heart failure 1.38 [0.45; 4.25] Ventricular fibrillation 0.66 [0.11; 3.88] II-III heart block 1.38 [0.45; 4.25] |
| Gyamlani, 2000 | vs placebo | Ventricular tachycardia 0.27 [0.08; 0.92] All cause death 0.20 [0.05; 0.87] Heart failure 0.60 [0.36; 1.00] II-III heart block 0.60 [0.36; 1.00] | | Ventricular fibrillation 0.00 [0.00; NaN] Cardiogenic shock 0.40 [0.08; 1.97] Bradycardia ∞ [NaN; ∞] |
| Ising, 1990 | vs placebo | | | |
| Morton, 1984 | vs placebo | | Heart failure 2.52 [1.01; 6.30] II-III heart block 2.52 [1.01; 6.30] | All cause death 0.45 [0.04; 4.76] Profound hypotension ∞ [NaN; ∞] Ventricular fibrillation 1.80 [0.17; 19.02] |
| Nakashima, 2004 | vs placebo | | | All cause death 0.34 [0.04; 3.22] Heart failure 0.66 [0.39; 1.10] Ventricular fibrillation 1.79 [0.54; 5.90] II-III heart block 0.66 [0.39; 1.10] Cardiogenic shock 0.85 [0.39; 1.87] |
| Parikka, 1990 | vs placebo | | | Heart failure 0.98 [0.38; 2.55] II-III heart block 0.98 [0.38; 2.55] |
| Raghu, 1999 | vs placebo | All cause death 0.36 [0.15; 0.88] | | Bradycardia ∞ [NaN; ∞] |
| Rasmussen, 1986 | vs placebo | | | Ventricular tachycardia 0.93 [0.38; 2.28] All cause death 0.38 [0.13; 1.08] Heart failure 1.32 [0.08; 20.67] II-III heart block 1.32 [0.08; 20.67] Cardiogenic shock 0.00 [0.00; NaN] severe arrhythmia 1.13 [0.57; 2.25] Bradycardia 0.44 [0.09; 2.10] |
| Santoro, 2000 | vs placebo | | | Ventricular tachycardia 1.64 [0.83; 3.22] All cause death 0.00 [0.00; NaN] Heart failure 1.20 [0.38; 3.76] II-III heart block 1.20 [0.38; 3.76] Bradycardia ∞ [NaN; ∞] |
| Shechter, 1990 | vs placebo | All cause death 0.12 [0.02; 0.90] | | Heart failure 0.84 [0.48; 1.46] II-III heart block 1.06 [0.55; 2.06] Cardiogenic shock 0.18 [0.02; 1.42] severe arrhythmia 0.71 [0.43; 1.17] |
| Shechter, 1991 | vs placebo | | | All cause death 0.60 [0.12; 2.93] II-III heart block 0.71 [0.31; 1.64] Cardiogenic shock 0.30 [0.04; 2.46] severe arrhythmia 0.68 [0.36; 1.30] |
| Shechter, 1995 | vs placebo | All cause death 0.24 [0.08; 0.69] Cardiogenic shock 0.09 [0.01; 0.70] | | II-III heart block 0.84 [0.48; 1.46] severe arrhythmia 0.68 [0.45; 1.02] |
| Singh, 1990 | vs placebo | severe arrhythmia 0.37 [0.20; 0.67] | | All cause death 0.55 [0.21; 1.40] Profound hypotension 1.67 [0.79; 3.54] Cardiogenic shock 1.00 [0.26; 3.83] |
| Smith, 1986 | vs placebo | | | All cause death 0.29 [0.06; 1.35] severe arrhythmia 0.72 [0.24; 2.19] |
| Thogersen, 1995 | vs placebo | | | All cause death 0.47 [0.14; 1.52] |
| Urek, 1996 | vs placebo | | | All cause death ∞ [NaN; ∞] II-III heart block 0.97 [0.06; 14.78] severe arrhythmia 0.62 [0.28; 1.38] |
| Woods, 1992 | vs placebo | All cause death 0.76 [0.59; 0.99] Heart failure 0.75 [0.61; 0.93] II-III heart block 0.75 [0.61; 0.93] | Bradycardia 1.34 [1.04; 1.73] | Profound hypotension 1.00 [0.70; 1.43] |
| Wu, 1992 | vs placebo | Ventricular tachycardia 0.29 [0.11; 0.78] All cause death 0.34 [0.12; 0.93] Ventricular fibrillation 0.12 [0.01; 0.93] severe arrhythmia 0.39 [0.23; 0.64] | | Heart failure 0.86 [0.48; 1.55] II-III heart block 0.86 [0.48; 1.55] |
| Zhu, 2002 | vs placebo | All cause death 0.66 [0.52; 0.85] Ventricular fibrillation 0.52 [0.35; 0.80] | | Cardiogenic shock 0.66 [0.42; 1.03] |
| Trial | Treatments | Patients | Method |
|---|
| Abraham, 1987 | 2.4g of magnesium sulfate in 50 ml of 5% glucose solution intravenously over a 20 minutes period for 3 days (n=48) vs. 50 ml of 5% glucose solution alone, imag (n=46) | patients with AMI | double blind Parallel groups Sample size: 48/46 Primary endpoint: FU duration: |
| ISIS-4, 1995 | 24 h of intravenous magnesium sulphate (8 mmol initial bonus injection over about 15
minutes followed by 72 mmol in about 50 mLinfused over 24 h)4 (n=29011) vs. no magnesium infusion (n=29030) | patients entering 1086 hospitals up to 24 h (median 8 h) after the onset of suspected acute myocardial
infarction with no clear contraindications4 | open Parallel groups Sample size: 29011/29030 Primary endpoint: FU duration: |
| MAGIC, 2000 | 2 g intravenous bolus of MgSO4 over 15 minutes, followed by a 17 g infusion of MgSO4
over 24 h (n=3113) vs. matched intravenous bolus and 24 h infusion of sterile waterndºã (n=3100) | AMi patients within 6 h of onset of symptomsm | double blind Parallel groups Sample size: 3113/3100 Primary endpoint: FU duration: |
| Bhargava, 1995 | 8 mmol magnesium sulphate over 5 min followed by 65 mmol over 24-h infusion (n=40) vs. isotonic saline infusion (n=38) | proven AMI patients with chest pain of 1-6h | double blind Parallel groups Sample size: 40/38 Primary endpoint: FU duration: |
| Ceremuzynski, 1989 | 8 g MgSO4 in 500 mL 15% glucose for 24 h intravenouslypj (n=25) vs. conventional treatmenton (n=23) | patients with AMI within 12 h from onset of symptomslypj | NA Parallel groups Sample size: 25/23 Primary endpoint: FU duration: |
| Chen, 1991 | MgSO4 2g/day for 3 daysn (n=32) vs. 5% glucose (n=30) | patients with AMI | open blind assessor Parallel groups Sample size: 32/30 Primary endpoint: FU duration: |
| Feldstedt, 1991 | continuous infusion of 80 mmol magnesium chloride in 1000 mL dextrose˜K (n=150) vs. matching placebo (n=148) | patients, aged 75 y or less, with suspected AMI less than 8 h+—² | double blind Parallel groups Sample size: 150/148 Primary endpoint: FU duration: |
| Gyamlani, 2000 | magnesium 12g (50 mmol) in the first 24h, 3g (12 mmol) in the second 24h used within 2h after admission and within 30 minutes of thrombolytic therapy™ (n=50) vs. equal volume of isotonic glucose (n=50) | patients with proven AMI | double blind Parallel groups Sample size: 50/50 Primary endpoint: FU duration: |
| Ising, 1990 | 81 mval/daymagnesium sulphate infusion 13+/-9h after the onset of severe pain for 3 days (n=22) vs. 80 mval/day NaCl infusion for 3 daysimag (n=20) | patients with AMI | open Parallel groups Sample size: 22/20 Primary endpoint: FU duration: |
| Morton, 1984 | 36 h intravenous infusion of magnesium sulphate (0.75 mEq/kg/body weight/12 h). (n=-9) vs. saline solution infusion (n=-9) | patients with AMI within 8 h of onsetmag | double blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: |
| Nakashima, 2004 | bolus injection of 8 mmol of magnesium followed by an infusion of 24 mmol over 24 h (n=89) vs. equivalent amount of normal saline, imag (n=91) | patients with successful PCI weree, imag | double blind Parallel groups Sample size: 89/91 Primary endpoint: FU duration: |
| Parikka, 1990 | 8mmol MgSO4 in 10 min, 62 mmol in 24hmag (n=31) vs. NaCl ¯B (n=26) | patients with < 12 h from onset of chest pain AMImage/pj | double blind Parallel groups Sample size: 31/26 Primary endpoint: FU duration: |
| Raghu, 1999 | 18 g (75.6 mmol) of Mg sulphate over 24 h started immediately after completion of thrombolytic
therapy (n=181) vs. equivalent amount of salinexbitm (n=169) | confirmed AMI < 6 h from the onset of symptomsce | double blind Parallel groups Sample size: 181/169 Primary endpoint: FU duration: |
| Rasmussen, 1986 | 50 mmol MgCl2 during the first 24 h, 12 mmol during the second 24 h (n=56) vs. isotonic glucose (n=74) | patients with suspected AMIxbitm | double blind Parallel groups Sample size: 56/74 Primary endpoint: FU duration: |
| Santoro, 2000 | MgSO4 7 g (28 mmol) with 5 hon (n=75) vs. matching saline solution (n=75) | | double blind Parallel groups Sample size: 75/75 Primary endpoint: FU duration: |
| Shechter, 1990 | magnesium 22 g (91.6 mmol) within 48 h (67 mmol within first 24 h). (n=50) vs. isotonic glucose. (n=53) | patients with admission diagnosis of AMI | double blind Parallel groups Sample size: 50/53 Primary endpoint: FU duration: |
| Shechter, 1991 | 22 g (91.6 mmol) within 48 h (67 mmol within first 24 h). (n=21) vs. isotonic glucose. (n=25) | patients with documented AMIbitm | double blind Parallel groups Sample size: 21/25 Primary endpoint: FU duration: |
| Shechter, 1995 | magnesium 22 g (91.6mmol) within 48 h (67mmol within first 24 h)pj (n=96) vs. isotonic glucose (n=98) | suspected with AMI and considered unsuitable candidates for thrombolysis | double blind Parallel groups Sample size: 96/98 Primary endpoint: FU duration: |
| Singh, 1990 | 5 g (8.12 mmol) of MgSO4 daily for 4 daysptomsce (n=-9) vs. 2% dextrose solution for 3 daysm (n=-9) | patients suspected with AMI within 8-12h of the onset of MI | double blind Parallel groups Sample size: -9/-9 Primary endpoint: FU duration: |
| Smith, 1986 | 65 mmol MgSO4 given over 24 h (n=92) vs. Saline (n=93) | patients with suspected AMI h.tm | double blind Parallel groups Sample size: 92/93 Primary endpoint: FU duration: |
| Thogersen, 1995 | magensium 50 mmol within 24 h (n=130) vs. isotonic NaCl. (n=122) | patients with suspected AMI | double blind Parallel groups Sample size: 130/122 Primary endpoint: FU duration: |
| Urek, 1996 | 17 g MgSO4 with first 24 h.xbitm (n=31) vs. saline. (n=30) | patients with documented AMIbitm | double blind Parallel groups Sample size: 31/30 Primary endpoint: FU duration: |
| Woods, 1992 | magnesium 8 mmol over 5 min, 65 mmol over 24h imag (n=1159) vs. physiological saline hon (n=1157) | patients with suspected AMI in the preceding 24h | double blind Parallel groups Sample size: 1159/1157 Primary endpoint: FU duration: |
| Wu, 1992 | 2.5 g MgSO4 once or twice a day for 7-14 dayssce (n=125) vs. usual care (n=102) | suspected AMI | double blind Parallel groups Sample size: 125/102 Primary endpoint: FU duration: |
| Zhu, 2002 | 100 mL (4 g) potassium-magnesium aspartate IV. for the first day, 50 ml for rest 4 datio (n=1691) vs. routine AMI treatmentƒkB (n=1488) | AMI | open Parallel groups Sample size: 1691/1488 Primary endpoint: FU duration: |
